metaEvidence - overview


			deaths (OS)
metastatic (mCRPC) - 1st line (L1) castration-resistant prostate cancer (CRPC) metastatic (mCRPC) - 1st line (L1)
metastatic, hormone-sensitive prostate cancer metastatic, hormone-sensitive prostate cancer
versus androgen deprivation therapy (ADT)
	abiraterone plus ADT vs. androgen deprivation therapy (ADT)	2	NaN [NaN; NaN] /10000 0/0 vs. 0/0
	apalutamide plus ADT vs. androgen deprivation therapy (ADT)	1	NaN [NaN; NaN] /10000 0/0 vs. 0/0
	docetaxel plus ADT vs. androgen deprivation therapy (ADT)	4	NaN [NaN; NaN] /10000 0/0 vs. 0/0
	enzalutamide plus ADT vs. androgen deprivation therapy (ADT)	2	NaN [NaN; NaN] /10000 0/0 vs. 0/0
versus docetaxel plus ADT
	abiraterone plus docetaxel plus ADT vs. docetaxel plus ADT	1	NaN [NaN; NaN] /10000 0/0 vs. 0/0
	darolutamide plus doxetaxel plus ADT vs. docetaxel plus ADT	1	NaN [NaN; NaN] /10000 0/0 vs. 0/0